Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

U

UMC Utrecht

Status and phase

Completed
Phase 2
Phase 1

Conditions

Multiple Myeloma

Treatments

Drug: Lenalidomide, endoxan, prednisone
Drug: lenalidomide, endoxan, prednisone

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01352338
RV-MM-PI-0630

Details and patient eligibility

About

Study Phase: phase 1 and phase 2 Objective: Evaluation of the effect of lenalidomide, cyclophophamide and prednisone (REP) in patients with relapsed multiple myeloma previously treated with lenalidomide Study design: prospective, multicenter, non-randomized

Full description

The REPEAT-study is a prospective, multicenter, non-randomized phase 1 and phase 2 study in which we evaluate the effect of lenalidomide, cyclophosphamide and prednisone (REP-therapy) in patients with relapsed multiple myeloma, previously treated with lenalidomide and refractory to lenalidomide monotherapy.

Enrollment

82 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • salmon & Durie stage II/III A or B
  • previous lenalidomide refractory disease
  • patient commits to pregnancy prevention programme

Exclusion criteria

  • non-secretory myeloma
  • known hypersensitivity to lenalidomide
  • inadequate marrow reserve

Trial design

82 participants in 1 patient group

lenalidomide, endoxan, prednisone
Experimental group
Description:
lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks. Lenalidomide is combined with endoxan and prednisone
Treatment:
Drug: Lenalidomide, endoxan, prednisone

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems